Search
RBC Healthcare Conference: After meeting with FDA numerous times over the last six months, MoonLake is preparing to file its BLA for sonelokimab in the fall
Founder, Chairman & CEO Jorge Santos da Silva walks us through the pivotal and other supporting data he believes makes this a compelling option in HA, and discusses preparations to file and beyond.
May 19
Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)
Jorge Santos da Silva walks us through the scientific design of the molecule, which is a nanobody that binds to IL-17A, IL-17F, and...
Jul 10, 2025
London Healthcare Week: The CEO of MoonLake Immunotherapeutics gives an overview of the company's Nanobody platform, including the lead program that targets IL-17A and IL-17F
Jorge Santos da Silva explains the properties that he believes give Nanobodies versatility and an edge over traditional antibodies, and...
Nov 18, 2024
.png){kind=logo}